- Conditions
- Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1026
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
Location Directory
Clinical trials in Nashville, Tennessee
This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10857
Shown on this page
12
Current sort
Recently updated
Location scope
Nashville, TN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 97–108 of 10,857 matching trials in Nashville, TN.
Live ClinicalTrials.gov results.
Institutions in Nashville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Huntington Disease
- Interventions
- Pridopidine, Placebo
- Drug
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 23 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- Placebo, Risankizumab
- Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 55
- States / cities
- Anniston, Alabama • Fullerton, California • Huntington Beach, California + 50 more
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
- Interventions
- TER-2013, Fulvestrant injection
- Drug
- Lead sponsor
- Terremoto Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Duarte, California • Irvine, California • Orlando, Florida + 14 more
- Conditions
- Advanced Solid Tumour
- Interventions
- BI 3968621, ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Atlanta, Georgia • Philadelphia, Pennsylvania + 2 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 21
- States / cities
- Duarte, California • Lone Tree, Colorado • Orlando, Florida + 16 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- bulumtatug fuvedotin
- Drug
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Duarte, California • La Jolla, California • Aurora, Colorado + 4 more
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- MILD, Interspinous Process Decompression
- Device
- Lead sponsor
- Stryker Instruments
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2384
- States / cities
- Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1286 more
- Conditions
- Parkinson Disease
- Interventions
- AP-472, Placebo
- Drug · Other
- Lead sponsor
- Appello Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
- Conditions
- Urothelial Cancer, Urinary Bladder Neoplasms
- Interventions
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 18 more
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Interventions
- Nerandomilast, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- PEGCETACOPLAN (APL-2)
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more